FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Friday

 

Multiple Sclerosis, Crohn’s Drug Used in HIV Targeted Therapy





























Multiple sclerosis (MS) and Crohn’s disease drug Tysabri (Biogen Idec Inc.) can be used to fight against human immunodeficiency virus (HIV), according to research published in PLOS Pathogens.

Researchers from Boston College treated 4 monkey models of HIV with high plasma virus and central nervous system injury with once weekly natalizumab (sold under the brand name Tysabri) initiated on 28 days post-infection. After 3 weeks, the drug reversed the lesions present on the central nervous system. Additionally, the virus track to the brain was blocked in monocytes and macrophages. This was significant, the researchers explained, because those cells collect in “viral reserves” which are associated with comorbidities that HIV patients sometimes have.

“We actually stopped all traffic and showed that if you physically block monocytes and macrophages, the virus does not enter the brain,” senior author Ken Williams, PhD said in a press release. “And even if full and major lesions of the central nervous system are present, application of the antibody can heal that damage and eliminate the virus, underscoring the necessity for continued traffic of cells to the central nervous system and the gut to maintain infection and lesions.”

The researchers also conducted a parallel trial over 3 weeks which measured the time of experimental infection. Natalizumab completed blocked the monocyte and macrophage traveling between the brain and the gut in animal models of HIV. The researchers explained that this research confirmed the role that monocytes play in preparing the central nervous system with virus and leukocytes. Both of these are early warning signs of a myriad of potential comorbidities, the authors said.

“So our question was if we can do that with HIV, does it stop virus replication in the brain, stop seeding and does it reverse injury?” continued Williams, who said that a “cure” for HIV or AIDS would essentially mean a destruction of these viral reservoirs. “The answer to each of those questions, we now know, is ‘yes’.”

Between these 2 studies, the investigators believe there are potential treatment regimens for HIV patients which include antibody medications in combination with anti retroviral drugs. This combination would simultaneously target reservoirs in the brain and the guy, while many current therapies target lymphoid organs to contain infection, Williams explained.

More studies involving humans are scheduled to begin in the spring, also to be lead by Williams. The $40 million clinical trial will be funded by the National Institute of Allergy and Infectious Disease and involve researchers from Massachusetts General Hospital. The research team will aim to evaluate whether treatment with a statin can reduce elevated risk of cardiovascular disease in HIV-positive patients.

Story Source: The above story is based on materials provided by HCPLIVE
Note: Materials may be edited for content and length


Go to Newer News Go to Older News